Auris Medical Holding (EARS) Reports Keyzilen TACTT2 Trial Missed co-Primary Efficacy Endpoints
Tweet Send to a Friend
Auris Medical Holding AG (Nasdaq: EARS) announced top-line results from the Phase 3 TACTT2 trial with Keyzilen (AM-101) in acute ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
